Table 5.
Clinicopathological predictors of SLNB in DCIS patients undergoing BCS
| Characteristic | BCS (n = 145) (%) | ||
|---|---|---|---|
| SLNB (n = 54, 37.2%) | None (n = 91, 62.8%) | p-value | |
| Preoperative tumour size, cm | < 0.001 | ||
| ≤ 2 | 27 (26.7) | 74 (73.3) | |
| > 2 and ≤ 5 | 27 (61.4) | 17 (38.6) | |
| > 5 cm | 0 (0.0) | 0 (0.0) | |
| Palpability | 0.011 | ||
| Non-palpable | 36 (31.6) | 78 (68.4) | |
| Palpable | 18 (58.1) | 13 (41.9) | |
| Mammographic calcification | 0.608 | ||
| Present | 30 (39.5) | 46 (60.5) | |
| Absent | 24 (34.8) | 45 (65.2) | |
| Ultrasonic mass-forming lesions | 0.012 | ||
| Present | 42 (45.2) | 51 (54.8) | |
| Absent | 12 (23.1) | 40 (76.9) | |
| Tumour location | 0.071 | ||
| Upper-outer | 26 (45.6) | 31 (54.3) | |
| Upper-inner | 13 (61.9) | 8 (38.1) | |
| Lower-outer | 8 (30.8) | 18 (69.2) | |
| Lower-inner | 7 (17.1) | 34 (82.9) | |
| Multicentric | 0 (0.0) | 0 (0.0) | |
| Biopsy method | < 0.001 | ||
| Core-needle biopsy | 47 (69.1) | 21 (30.9) | |
| VABB | 0 (0.0) | 6 (100.0) | |
| Excisional biopsy | 7 (9.9) | 64 (90.1) | |
| Comedo necrosis | 0.007 | ||
| Absent | 26 (28.6) | 65 (71.4) | |
| Present | 28 (51.9) | 26 (48.1) | |
| Main type of DCIS | 0.002 | ||
| Cribriform | 18 (25.0) | 54 (75.0) | |
| Comedo | 29 (55.8) | 23 (44.2) | |
| Solid | 7 (33.3) | 14 (66.7) | |
| Nuclear grade | 0.001 | ||
| Low | 7 (14.9) | 40 (85.1) | |
| Intermediate | 29 (46.8) | 33 (53.2) | |
| High | 18 (50.0) | 18 (50.0) | |
BCS breast-conserving surgery, DCIS ductal carcinoma in situ, SLNB sentinel lymph node biopsy, VABB vacuum-assisted breast biopsy